Unflavoured, once-daily powder combines dandelion extract, milk thistle, cascara sagrada, artichoke, turmeric, licorice extract, a probiotic blend and polyphenols targeting digestive regularity, gut microbiome balance and metabolic function in active adults, with an ingredient-by-ingredient research overview and no clinical trial conducted on the finished formula.
FOR IMMEDIATE RELEASE — OGDEN, Utah, Sept. 20, 2026 — The global digestive health products market was valued at approximately $55.8 billion in 2025 and is projected to reach $99.1 billion by 2034, according to IMARC Group estimates — a compound annual growth rate of 6.3 percent. Operating in that market, Finessa has released a powdered dietary supplement marketed for digestive support, colon health and liver function, priced from $39 to $59 per bottle and sold through the ClickBank retail platform at myfinessa.com.
The product is marketed primarily to adults over 18 in the United States. No individual creator or spokesperson is identified in the company’s product materials.
No randomized controlled clinical trial evaluating the complete Finessa formula has been cited by the company. The scientific references on the product page concern independent studies of individual ingredients — dandelion extract, milk thistle, cascara sagrada, artichoke, turmeric, licorice extract, probiotics and polyphenols — conducted separately from the finished Finessa product. Findings from those studies cannot be assumed to apply to the formulation as sold.
What the Product Is
Finessa is a powdered supplement sold in single-bottle, three-bottle and six-bottle configurations. The company instructs consumers to mix one scoop with water or another beverage once daily in the morning. The product is sold exclusively through the company’s own website and is not available through third-party retail channels including Amazon or pharmacies, according to the company’s FAQ section.
Three digital bonus items accompany orders of three or six bottles: a guide titled “Anti-Aging Superfoods,” a meal-timing guide titled “Cheat Your Way Slim,” and a smoothie recipe collection titled “Powerful Detox Smoothies.” These are digital downloads, not physical products.
The company’s marketing claims include references to a “flatter belly,” “smoother, more radiant skin,” “increased energy levels,” “faster digestion,” “sharper focus,” “healthy cholesterol,” “balanced blood sugar,” and “a revved-up metabolism” — none of which appears in the independent ingredient studies cited on the product page.
What Finessa Claims to Do and What the Evidence Shows
The product’s central marketing claim is that it targets the “gut-liver axis” — described on the company’s product page as a bidirectional communication system between the gut microbiota and the liver. The gut-liver axis is a recognized area of scientific research, though the existing body of evidence is focused primarily on liver disease pathology rather than consumer supplementation.
“Finessa was formulated to support the gut-liver connection that published research has increasingly identified as central to digestive function,” said Kevin Peter, Product Head at Finessa. “We reference the available ingredient-level science transparently, and we acknowledge that a finished-product clinical trial has not been conducted on this formulation.”
Research published in the International Journal of Molecular Sciences in 2023 examined how disruptions in gut bacterial homeostasis can activate immune responses contributing to liver disease progression. A March 2025 narrative review in Fundamental Research similarly described the gut-liver relationship as a pathway of clinical significance in diagnosed liver disease. Neither study examined the use of multi-ingredient powdered supplements by healthy adults.
The NIH National Center for Complementary and Integrative Health addresses this distinction directly in its published consumer guidance: “The fact that a dietary supplement contains a naturally occurring substance does not mean that it is safe or effective. Many supplements have not been tested in people, and research is often lacking on how they interact with foods, medicines, or other supplements.”
The product’s individual ingredients are cited against a list of referenced studies. Several of those studies concern extract concentrations, delivery methods and patient populations that differ from the Finessa formulation.
Ingredient-Level Research: What Studies Show and Do Not Show
The company cites published research for each of the eight ingredients in the Finessa formula. An independent review of those citations reveals the following:
Dandelion (Taraxacum): A 2011 study cited by the company examined the effect of dandelion on gastric emptying in rodents. Rodent studies are not directly applicable to human outcomes.
Milk Thistle (Silymarin): The cited research concerns liver function and liver stiffness in patients with metabolic liver disease — a clinical population distinct from the general consumer audience the product targets.
Cascara Sagrada: The company cites a University of Rochester reference and a 1997 systematic review on chronic constipation treatment in adults. Cascara sagrada contains anthraquinone compounds that act as stimulant laxatives. The FDA banned over-the-counter use of cascara sagrada in laxative products in 2002 on the grounds that safety and efficacy data were insufficient at the time; the ingredient has since re-entered the supplement market under dietary supplement regulations, which do not require pre-market efficacy proof.
Probiotics: The company cites a meta-analysis of 14 clinical trials showing probiotics increased bowel movements by 1.3 per week and reduced gut transit time by 12.4 hours. This is one of the stronger evidence citations on the product page; however, the specific probiotic strains, doses and populations used in those trials are not matched to the Finessa formulation, and the company does not disclose which probiotic strains are included or at what colony-forming unit count.
Turmeric (Curcumin): A 2023 study cited by the company was published in Frontiers in Microbiology. Curcumin has been extensively studied but is known to have low oral bioavailability without specific delivery mechanisms such as piperine or phospholipid complexes. The company does not disclose whether the Finessa formula includes any bioavailability-enhancing agents.
Polyphenols: The company cites a 2020 study in the Journal of Functional Foods on polyphenols and gut bacteria. Polyphenols are a broad class of compounds found in thousands of plant foods; without specifying which polyphenols are included and at what dose, the citation cannot be applied to the product.
For all eight ingredients, the company does not disclose specific quantities. The National Institutes of Health Office of Dietary Supplements notes that ingredient quantity is a critical factor in assessing whether a supplement formulation is consistent with research doses.
Market Context
The global digestive health supplements market was valued at approximately $15.49 billion in 2024 and is projected to grow to $33.93 billion by 2033, at a compound annual growth rate of 9.1 percent, according to market research estimates. Driving factors cited by analysts include rising prevalence of gastrointestinal disorders, growing consumer awareness of gut health, and increased interest in preventive health products.
The proliferation of gut health supplements has drawn regulatory attention. Under current federal regulations, supplement manufacturers are not required to prove safety or efficacy before bringing a product to market — a structure that places the burden of post-market enforcement on the FDA rather than requiring pre-market proof.
The Federal Trade Commission addresses the evidentiary standard directly in its published guidance for dietary supplement advertisers: “Advertisers must have competent and reliable scientific evidence for all objective claims. Competent and reliable scientific evidence means tests, analyses, research, or studies that have been conducted and evaluated objectively by qualified persons and that are generally accepted in the profession to yield accurate and reliable results.” The FTC applies that standard to the finished product as sold — not to individual ingredients studied in isolation — and has brought enforcement actions against supplement companies whose ingredient-level citations did not constitute adequate substantiation for finished-product claims.
Regulatory Classification and Disclaimers
Finessa is classified as a dietary supplement and is regulated by the FDA as a food product, not a drug. Pre-market approval is not required for dietary supplements provided no drug claims are made.
The company’s website footer states: “These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.” This language is required by federal regulation for dietary supplement marketing.
The company’s terms page states that the product is not a substitute for professional medical advice, diagnosis or treatment and that individuals with medical conditions should consult a physician before use. The terms place full responsibility for individual outcomes on the consumer.
The company’s checkout page includes ClickBank’s standard retailer disclosure stating that ClickBank’s role as retailer does not constitute an endorsement, approval or review of the product.
The company recommends a minimum of six months of continuous use to experience the product’s stated benefits. No clinical study on the finished Finessa formula is cited to support that recommended duration.
Product Availability and Refund Policy
Finessa is available exclusively at official website through the ClickBank retail platform. Pricing is as follows: one bottle (30-day supply) at $59; three bottles (90-day supply) at $49 per bottle; six bottles (180-day supply) at $39 per bottle. The company states that three- and six-bottle orders include free U.S. shipping.
The company offers a 180-day money-back refund policy, administered through ClickBank. Consumers should verify current refund terms directly on the checkout page before purchase, as terms are subject to change.
The company has not disclosed the probiotic strains included in the formula or their colony-forming unit counts, the manufacturing facility’s name or location beyond a reference to GMP certification, or the identity of the product’s formulator or scientific advisory team.
About Finessa
Finessa is a dietary supplement brand producing a powdered digestive health formula containing eight botanical and probiotic ingredients. The company states the product is manufactured in a facility certified under Good Manufacturing Practices. The company distributes its product through the ClickBank retail platform at myfinessa.com.
Media Contact
Kevin Peter, Product Head
Finessa
PO Box 12730, Ogden, UT 84412, United States
Email: support@myfinessa.com
Phone: (863) 591-4284
Website: myfinessa.com
This press release is issued by Finessa and reflects the company’s own statements about its product alongside independently sourced scientific and regulatory information. The scientific studies cited are independent peer-reviewed research; their citation does not imply that the researchers, authors, journals or institutions involved have evaluated, tested or endorsed the Finessa formula or any claims associated with it. Finessa is regulated as a dietary supplement under the Dietary Supplement Health and Education Act of 1994 and has not been approved by the U.S. Food and Drug Administration. Individual results vary. This release is for informational purposes only and does not constitute medical, nutritional or legal advice. Consumers with existing medical conditions should consult a licensed healthcare provider before use.
The post Finessa Reviews: Launches Eight-Ingredient Daily Powder Supplement for Digestive and Gut Health in the U.S. appeared first on 24 Health Times.
